Wednesday 26 June 2024

Recce Pharmaceuticals (ASX:RCE) reveals successful batch completion under Good Manufacturing Practices

Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), a company developing a New Class of Synthetic Anti-Infectives, announces successful batch completion under Good Manufacturing Practices (GMP) for RECCE® 327 with the patented manufacturing process now producing 5,000 GMP doses of R327 per week.


  • Successful production of 5,000 x RECCE® 327 (R327) doses per week under GMP campaign.
  • R327 manufactured under GMP standards in support of present Phase I, Phase II and anticipated Registrational Phase III clinical trials, demonstrating compliance with guidelines set by regulatory authorities, such as the U.S. Food and Drug Administration.



Recce Pharmaceuticals’ Head of Manufacturing Arthur Kollaras said “We are thrilled to
announce the successful batch completion of human pharmaceutical grade R327, representing
a crucial step forward in our mission to address the global threat of antimicrobial resistance.”

Free stock updates

Subscribe to receive the latest stock news, CEO interviews, expert insights, events and offers directly into your inbox